Metabolic risk factors and BMI-associated variants influencing weight loss with Semaglutide

Since 2017, Semaglutide and other Glucagon-like-peptide-1 (GLP-1) receptor agonists have revolutionized the treatment for type 2 diabetes and now with FDA extension for chronic weight management, as well. Despite the drug’s proven efficacy, there has been significant heterogeneity in the degree of weight loss experienced by users with contributing factors remaining unclear. In this research webinar and Q&A, learn about how weight loss with semaglutide is influenced by traditional metabolic risk factors and genetic variants associated with Body Mass Index (BMI) changes. Key learnings include:

• Identifying demographic and metabolic factors associated with weight loss trajectories over 12 months following initiation of semaglutide
• Evaluate the impact of an established BMI polygenic score (PGS)
• Helix’s precision clinical research network and clinico-gneomic virtual registry for GLP-1 agonist treated patients

Webinar Speakers:

Dr. Matt Levy, Senior Research Scientist

Jay Shah, Marketing Director, Life Sciences